Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Baricitinib works better in adolescents than adults for treating severe alopecia areata.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

Patients with alopecia areata on ritlecitinib responded well to tetanus and meningococcal vaccines.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

Baricitinib may effectively treat nail changes in alopecia areata.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

The combination therapy is effective and well-tolerated for treating esophageal cancer.

Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.

Upadacitinib may effectively treat resistant lichen planopilaris.

Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

Aminopterin was somewhat effective in acute lymphoblastic leukemia in children but did not increase survival time.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Ritlecitinib improves hair growth and quality of life in severe alopecia areata with longer use.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Abrocitinib may effectively treat stubborn alopecia universalis.

Kanglaite injection with chemotherapy improves treatment and reduces side effects for advanced lung cancer.

Deuruxolitinib and baricitinib are effective for treating severe alopecia areata.

The gel improves hair regrowth and reduces irritation in alopecia areata treatment.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Regional prescribing of ritlecitinib mostly follows national guidance, but psychological assessments and consistent scoring need improvement.